The synthesis and use of a novel class of tumor necrosis factor (TNF)
inhibitors and immunomodulators are provided. These compounds have pharmacological
applications as well as uses in assays relating to TNF and other involved
cytokines. As pharmaceuticals, these compounds are used to treat inflammatory,
infectious, autoimmune or other proliferative diseases and conditions related to
the unwanted presence or activity of TNF and/or one or more other involved
cytokines, alone or in combination with other agents. Examples of compounds of
the present invention are those having the structures as shown below:
##STR1##
wherein, a, b and c may be the same or different and are integers from 0
to 12, X equals NH or CHNH2, R1 and R2 can be
the same or different and equal to a hydrogen or a straight or branched C1
to C20 saturated or unsaturated aliphatic; aliphatic amine; an
alicyclic; single or multi-ring aromatic; a single or multi-ring aromatic heterocycle;
a single or multi-ring saturated heterocycle and the halogenated forms thereof;
and
##STR2##
- wherein, a, b and c may be the same or different and are integers from
0 to 12; R1, R2, R3, and R4 can be
the same or different and equal to a hydrogen or a straight or branched C1
to C20 saturated or unsaturated aliphatic; aliphatic amine; an
alicyclic; single or multi-ring aromatic; a single or multi-ring aromatic heterocycle;
a single or multi-ring saturated heterocycle and the halogenated forms thereof.
|
|
|
